Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Tuesday 15 May 2018, 10:00 – 17:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh, Chair Present for all notes
2. Dr Lindsay Smith Present for all notes
3. Dr Nabeel Alsindi Present for all notes
4. Dr Aomesh Bhatt Present for all notes
5. Dr Matthew Bradley Present for all notes
6. Prof. David Bowen Present for all notes
7. Mrs Susan Dutton Present for all notes
8. Professor Rachel Elliott Present for all notes
9. Mrs Gillian Ells Present for all notes
10. Professor Paula Ghaneh Present for all notes
11. Dr Peter Hall Present for all notes
12. Dr Robert Hodgson Present for all notes
13. Dr Bernard Khoo Present for all notes
14. Dr David Meads Present for all notes
15. Libby Mills Present for all notes
16. Malcolm Oswald Present for all notes
17. Professor Oluwafemi Oyebode Present for all notes
18. Dr Paula Parvulescu Present for all notes

In attendance:
Ismahan Abdullah Administrator, National Institute for Health and Care Excellence Present for all notes
Mariana Bacelar ERG Representative, BMJ Group Excellence Present for notes 17 to 25
Lucy Beggs Technical Analyst, National Institute for Health and Care Excellence Present for notes 17 to 40
David Chandler Patient Expert nominated by Psoriasis and Psoriatic Arthritis Alliance Present for notes 1 to 13
Ross Dent Technical Analyst, National Institute for Health and Care Excellence Present for notes 1 to 16
Steve Edwards  ERG Representative, BMJ Group  Present for notes 17 to 25
Christian Griffiths  Technical Adviser, National Institute for Health and Care Excellence  Present for notes 17 to 27
Sabine Grimm  ERG Representative, Kleijnen Systematic Reviews  Present for notes 1 to 13
Kayleigh Kew  ERG Representative, BMJ Group  Present for notes 17 to 25
Helen Knight  Associate Director, National Institute for Health and Care Excellence  Present for all notes
Dr Eleanor Korendowych  Clinical Expert nominated by British Society for Rheumatology  Present for notes 1 to 13
Kate Moore  Project Manager, National Institute for Health and Care Excellence  Present for all notes
Dr Jon Packham  Clinical Expert nominated by British Society for Rheumatology  Present for notes 1 to 13
Xavier Pouwels  ERG Representative, Kleijnen Systematic Reviews  Present for notes 1 to 13
Carla Renton  Patient Expert nominated by Psoriasis Association  Present for notes 1 to 13
David Thomson  CDF team, NHS England  Present for notes 17 to 25
Nwamaka Umeweni  Technical Adviser, National Institute for Health and Care Excellence  Present for notes 1 to 16 and 28 to 40
Robert Wolff  ERG Representative, Kleijnen Representative  Present for notes 1 to 13

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ixekizumab for treating psoriatic arthritis after DMARDs, alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer and lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

2. The chair announced that this will be Susan Dutton's last committee meeting as a member of the Appraisal Committee and thanked her for her time.

3. Apologies were received from Rebecca Harmston and Sumithra Maheswaran.
Any other Business

4. None

Appraisal of ixekizumab for treating psoriatic arthritis after DMARDs

Part 1 – Open session

5. The Chair welcomed the invited experts: David Chandler, Sabine Grimm, Dr Jon Packman, Xavier Pouwels, Carla Renton and Robert Wolff to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Eli Lilly to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Robert Hodgson, Dr Bernard Khoo, Dr David Meads, Libby Mills, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Lindsay Smith all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of Ixekizumab for treating active psoriatic arthritis after DMARDs.

7.2. Dr Peter Hall declared an indirect interest as his department within NHS Lothian has received research funding from Novartis and Pfizer for an unrelated topic.
7.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

7.3. Susan Dutton declared an indirect financial interest as she is involved in a psoriatic arthritis trial. The trial is funded by an NIHR Clinical Scientist Award and includes funding for the Oxford Clinical trials Research Unit (OCTRU), University of Oxford. She is fully funded by OCTRU and will be overseeing the statistician working in the trial management group.
7.3.1. It was agreed that this declaration would not prevent Susan Dutton from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of Ixekizumab for treating active psoriatic arthritis after DMARDs.

9. The Chair asked all other invited guests to declare their relevant interests.

9.3. David Chandler, Sabine Grimm, Xavier Pouwels, Carla Renton and Robert Wolff all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of Ixekizumab for treating active psoriatic arthritis after DMARDs.

9.4. Dr Jon Packham declared an indirect interest as his wife runs a training and consultancy business supplying the pharmaceutical industry.
9.4.1. It was agreed that this declaration would not prevent Dr Packham from participating in this section of the meeting.

10. The Chair introduced the lead team, Dr Nabeel Alsindi and Malcolm Oswald who gave presentations on the clinical effectiveness and cost effectiveness of ixekizumab for treating psoriatic arthritis after DMARDs.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of ixekizumab for treating psoriatic arthritis after DMARDs.

15.3. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer

Part 1 – Open session

17. The Chair welcomed the invited experts: Mariana Bacelar, Steve Edwards, Kayleigh Kew and David Thomson to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from Roche to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.3. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Robert Hodgson, Dr Bernard Khoo, Dr David Meads, Libby Mills, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Lindsay Smith all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
19.4. Dr Peter Hall declared an indirect interest as his department within NHS Lothian has received research funding from Novartis and Pfizer for an unrelated topic.  
19.4.1. It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

20. The Chair asked all NICE Staff to declare any relevant interests.

20.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal.

21. The Chair asked all other invited guests to declare their relevant interests.

21.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal.

22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.

26.3. The Committee continued to discuss the clinical and cost effectiveness of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.

26.4. The committee decision was based on consensus.

27. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine

Part 1 – Open session
28. The Chair welcomed the invited expert: David Thomson to the meeting and they introduced themselves to the Committee.

29. The Chair welcomed company representatives from Bayer and Eisai to the meeting.

30. The Chair asked all Committee members to declare any relevant interests

30.3. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Prof. David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Prof. Rachel Elliott, Mrs Gillian Ells, Prof. Paula Ghaneh, Dr Robert Hodgson, Dr Bernard Khoo, Dr David Meads, Libby Mills, Mr Malcolm Oswald, Prof. Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Lindsay Smith all declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

30.4. Dr Peter Hall declared an indirect interest as his department within NHS Lothian has received research funding from Novartis and Pfizer for an unrelated topic.

30.4.1. It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

31. The Chair asked all NICE Staff to declare any relevant interests.

31.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

32. The Chair asked all other invited guests to declare their relevant interests.

32.3. All declared that they knew of no direct or indirect interests for any of the technologies to be considered as part of the appraisal of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

33. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

34. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

35. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

36. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

37. Discussion on confidential information continued. This information was supplied by the company.
38. The Committee continued to discuss the clinical and cost effectiveness of lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.

38.3. The committee decision was based on consensus.

39. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

40. Tuesday 12 June 2018, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.